The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway
The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive c...
Saved in:
Published in | Food & function Vol. 14; no. 7; pp. 3155 - 3168 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Royal Society of Chemistry
03.04.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 2042-6496 2042-650X 2042-650X |
DOI | 10.1039/D2FO02191A |
Cover
Abstract | The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment.
Ganoderma lucidum
polysaccharide (GLPS) is a major bioactive component of
Ganoderma lucidum
, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group
in vivo
.
In vitro
, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling. |
---|---|
AbstractList | The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment.
Ganoderma lucidum
polysaccharide (GLPS) is a major bioactive component of
Ganoderma lucidum
, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group
in vivo
.
In vitro
, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling. The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo. In vitro, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling. The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. polysaccharide (GLPS) is a major bioactive component of , a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group . , the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling. The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo. In vitro, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo. In vitro, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling. |
Author | Zhao, Shuang Wang, Ya-ping Tan, Wen-li Zeng, Di Tang, Jia-feng Li, Jing Chen, Di-long Li, Guo-li Zhang, Tao Ran, Jian-hua |
Author_xml | – sequence: 1 givenname: Guo-li orcidid: 0000-0002-4983-1441 surname: Li fullname: Li, Guo-li organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China – sequence: 2 givenname: Jia-feng surname: Tang fullname: Tang, Jia-feng organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China – sequence: 3 givenname: Wen-li surname: Tan fullname: Tan, Wen-li organization: Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China – sequence: 4 givenname: Tao surname: Zhang fullname: Zhang, Tao organization: Neuroscience Research Center, College of Basic Medicine, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China – sequence: 5 givenname: Di surname: Zeng fullname: Zeng, Di organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China – sequence: 6 givenname: Shuang surname: Zhao fullname: Zhao, Shuang organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China – sequence: 7 givenname: Jian-hua surname: Ran fullname: Ran, Jian-hua organization: Neuroscience Research Center, College of Basic Medicine, Chongqing Medical University, Chongqing, PR China – sequence: 8 givenname: Jing surname: Li fullname: Li, Jing organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China – sequence: 9 givenname: Ya-ping surname: Wang fullname: Wang, Ya-ping organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China – sequence: 10 givenname: Di-long surname: Chen fullname: Chen, Di-long organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36883482$$D View this record in MEDLINE/PubMed |
BookMark | eNptkc9u1DAQxi1UREvphQdAlrggpFDHTrz2cSlsQRTKoUjcoon_bFwldmonoOVleA8egmfCoV0hVfgy1uj3fTP65jE68MEbhJ6W5FVJmDx9QzeXhJayXD9AR5RUtOA1-Xqw_1eSH6KTlK5JfkxKIcUjdMi4EKwS9Aj9vOoMBj-5ojMjTEGZvp97iFhBVM6HAbCx1qgp4WDxGPpdAqU6iE6bhG0MAz4HH7SJmexn5fQ84HaHo9lmm8n5LR5AxTB2sDWLPit_5H7w-JsDPOXpH9efP5x-2hS_f73GyW099IsqL9N9h90T9NBCn8zJXT1GXzZvr87eFReX5-_P1heFYnU5FYxpQ63k0FqqeClsbaq2JURz1dblijMtW0IFh8zp1ubKiVErJSjXSrGKHaMXt75jDDezSVMzuLSEAd6EOTV0JSrBZC1FRp_fQ6_DHPPaCyWZpDWXMlPP7qi5HYxuxugGiLtmH30GyC2Q00kpGtsoN_1NZorg-qYkzXLg5t-Bs-TlPcne9T_wH4CSqKA |
CitedBy_id | crossref_primary_10_1016_j_apsb_2024_05_032 crossref_primary_10_1016_j_fitote_2024_106150 crossref_primary_10_1016_j_biopha_2024_116161 crossref_primary_10_3390_molecules28196816 crossref_primary_10_1016_j_ijbiomac_2024_134757 crossref_primary_10_12677_ACM_2023_1381829 crossref_primary_10_1016_j_ijbiomac_2024_138575 crossref_primary_10_3390_nu16111642 crossref_primary_10_3390_foods13172665 crossref_primary_10_3390_foods13101578 crossref_primary_10_1016_j_ijbiomac_2024_138513 crossref_primary_10_1039_D3FO04166B crossref_primary_10_1016_j_ijbiomac_2024_133171 crossref_primary_10_1016_j_ijbiomac_2025_140645 crossref_primary_10_3892_ol_2024_14796 crossref_primary_10_1038_s41598_025_86977_x crossref_primary_10_3390_ijms26062684 crossref_primary_10_1002_eji_202451139 crossref_primary_10_1016_j_heliyon_2023_e17116 |
Cites_doi | 10.1016/j.addr.2017.04.010 10.2147/JIR.S307801 10.1002/kjm2.12020 10.1016/S1471-4906(02)02302-5 10.2147/JHC.S300165 10.1007/s00441-014-2083-6 10.1002/hep.26754 10.1016/j.ijbiomac.2015.10.088 10.3389/fimmu.2021.642842 10.3390/molecules23030649 10.1016/B978-0-12-417028-5.00006-5 10.3390/ijms22136894 10.1186/s12967-015-0465-5 10.3109/1061186X.2012.697167 10.1016/j.coph.2017.04.007 10.4254/wjh.v7.i2.165 10.1038/nm.3394 10.1038/ni.1990 10.1039/D0BM01142H 10.1186/s13075-021-02512-z 10.1016/j.chemosphere.2017.08.070 10.3389/fimmu.2021.660065 10.1177/1534735418762537 10.3390/cells9010046 10.1016/j.phymed.2022.154228 10.4161/auto.23546 10.1016/j.carbpol.2018.10.028 10.1080/2162402X.2021.1897295 10.1016/j.jconrel.2016.07.018 10.1172/JCI59643 10.3390/ijms22105196 10.2478/v10007-011-0030-6 10.1002/ptr.4980 10.4049/jimmunol.169.5.2253 |
ContentType | Journal Article |
Copyright | Copyright Royal Society of Chemistry 2023 |
Copyright_xml | – notice: Copyright Royal Society of Chemistry 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7T7 7TO 7U7 8FD C1K FR3 H94 P64 7X8 |
DOI | 10.1039/D2FO02191A |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Oncogenes and Growth Factors Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts Technology Research Database Toxicology Abstracts AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | CrossRef Oncogenes and Growth Factors Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Diet & Clinical Nutrition |
EISSN | 2042-650X |
EndPage | 3168 |
ExternalDocumentID | 36883482 10_1039_D2FO02191A |
Genre | Journal Article |
GroupedDBID | --- 0-7 0R~ 4.4 53G 705 7~J AAEMU AAHBH AAIWI AAJAE AANOJ AARTK AAWGC AAXHV AAYXX ABASK ABDVN ABEMK ABJNI ABPDG ABRYZ ABXOH ACGFS ACLDK ACPRK ADMRA ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFRAH AFRZK AFVBQ AGEGJ AGRSR AHGCF AKBGW AKMSF ALMA_UNASSIGNED_HOLDINGS ANUXI APEMP ASKNT AUDPV AZFZN BLAPV BSQNT C6K CITATION EBS ECGLT EE0 EF- GGIMP H13 HZ~ H~N J3I O-G O9- P2P RAOCF RCNCU RNS RPMJG RSCEA RVUXY SKF SKH SKJ SKM SKR SKZ SLC SLF CGR CUY CVF ECM EIF NPM 7T5 7T7 7TO 7U7 8FD C1K FR3 H94 P64 7X8 |
ID | FETCH-LOGICAL-c351t-33de2f96abf2c618f5e4bb00d6cb51763d9b0286a3dedbf6a360ec7c826dcc343 |
ISSN | 2042-6496 2042-650X |
IngestDate | Sat Sep 27 21:10:58 EDT 2025 Mon Jun 30 12:05:25 EDT 2025 Thu Apr 03 07:12:34 EDT 2025 Tue Jul 01 03:02:52 EDT 2025 Thu Apr 24 23:00:19 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c351t-33de2f96abf2c618f5e4bb00d6cb51763d9b0286a3dedbf6a360ec7c826dcc343 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-4983-1441 |
OpenAccessLink | https://pubs.rsc.org/en/content/articlepdf/2023/fo/d2fo02191a |
PMID | 36883482 |
PQID | 2793925699 |
PQPubID | 2047526 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_2784839598 proquest_journals_2793925699 pubmed_primary_36883482 crossref_citationtrail_10_1039_D2FO02191A crossref_primary_10_1039_D2FO02191A |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-04-03 |
PublicationDateYYYYMMDD | 2023-04-03 |
PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Cambridge |
PublicationTitle | Food & function |
PublicationTitleAlternate | Food Funct |
PublicationYear | 2023 |
Publisher | Royal Society of Chemistry |
Publisher_xml | – name: Royal Society of Chemistry |
References | Zhuang (D2FO02191A/cit24/1) 2021; 8 Francisco (D2FO02191A/cit19/1) 2021; 12 Heindryckx (D2FO02191A/cit11/1) 2015; 7 Zhu (D2FO02191A/cit20/1) 2019; 35 Joseph (D2FO02191A/cit12/1) 2011; 61 Sun (D2FO02191A/cit15/1) 2012; 20 Zeng (D2FO02191A/cit1/1) 2022; 103 Lu (D2FO02191A/cit35/1) 2021; 23 He (D2FO02191A/cit37/1) 2021; 22 Han (D2FO02191A/cit39/1) 2018; 191 Zhang (D2FO02191A/cit13/1) 2019; 205 Lang (D2FO02191A/cit31/1) 2002; 169 Sica (D2FO02191A/cit33/1) 2012; 122 Dehne (D2FO02191A/cit3/1) 2017; 35 Artemova (D2FO02191A/cit26/1) 2021; 22 Degroote (D2FO02191A/cit5/1) 2018 Pan (D2FO02191A/cit34/1) 2021; 14 Locati (D2FO02191A/cit29/1) 2013; 120 Mantovani (D2FO02191A/cit7/1) 2002; 23 Lu (D2FO02191A/cit17/1) 2014; 28 Wang (D2FO02191A/cit21/1) 2018; 17 Ngambenjawong (D2FO02191A/cit23/1) 2017; 114 Cor (D2FO02191A/cit22/1) 2018; 23 Avila-Ponce de Leon (D2FO02191A/cit25/1) 2021; 12 Sica (D2FO02191A/cit28/1) 2014; 59 Krausgruber (D2FO02191A/cit32/1) 2011; 12 Anfray (D2FO02191A/cit8/1) 2019; 9 Prabhu (D2FO02191A/cit2/1) 2021; 9 Chang (D2FO02191A/cit38/1) 2013; 9 Liu (D2FO02191A/cit16/1) 2016; 82 Mantovani (D2FO02191A/cit30/1) 2002; 23 Quail (D2FO02191A/cit27/1) 2013; 19 Capece (D2FO02191A/cit10/1) 2013 Lee (D2FO02191A/cit4/1) 2013; 1835 Li (D2FO02191A/cit14/1) 2015; 13 Lee (D2FO02191A/cit9/1) 2016; 240 Sun (D2FO02191A/cit18/1) 2015; 360 He (D2FO02191A/cit36/1) 2021; 10 Ngambenjawong (D2FO02191A/cit6/1) 2017; 114 |
References_xml | – volume: 114 start-page: 206 year: 2017 ident: D2FO02191A/cit23/1 publication-title: Adv. Drug Delivery Rev. doi: 10.1016/j.addr.2017.04.010 – volume: 14 start-page: 2045 year: 2021 ident: D2FO02191A/cit34/1 publication-title: J. Inflammation Res. doi: 10.2147/JIR.S307801 – volume: 35 start-page: 222 year: 2019 ident: D2FO02191A/cit20/1 publication-title: Kaohsiung J. Med. Sci. doi: 10.1002/kjm2.12020 – volume: 23 start-page: 549 year: 2002 ident: D2FO02191A/cit30/1 publication-title: Trends Immunol. doi: 10.1016/S1471-4906(02)02302-5 – volume: 8 start-page: 599 year: 2021 ident: D2FO02191A/cit24/1 publication-title: J. Hepatocell. Carcinoma doi: 10.2147/JHC.S300165 – volume: 360 start-page: 379 year: 2015 ident: D2FO02191A/cit18/1 publication-title: Cell Tissue Res. doi: 10.1007/s00441-014-2083-6 – volume: 59 start-page: 2034 year: 2014 ident: D2FO02191A/cit28/1 publication-title: Hepatology doi: 10.1002/hep.26754 – volume: 82 start-page: 973 year: 2016 ident: D2FO02191A/cit16/1 publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2015.10.088 – volume: 23 start-page: 549 year: 2002 ident: D2FO02191A/cit7/1 publication-title: Trends Immunol. doi: 10.1016/S1471-4906(02)02302-5 – volume: 12 start-page: 642842 year: 2021 ident: D2FO02191A/cit25/1 publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.642842 – start-page: 7819520 year: 2018 ident: D2FO02191A/cit5/1 publication-title: J. Immunol. Res. – volume: 23 start-page: 649 year: 2018 ident: D2FO02191A/cit22/1 publication-title: Molecules doi: 10.3390/molecules23030649 – volume: 120 start-page: 163 year: 2013 ident: D2FO02191A/cit29/1 publication-title: Adv. Immunol. doi: 10.1016/B978-0-12-417028-5.00006-5 – volume: 114 start-page: 206 year: 2017 ident: D2FO02191A/cit6/1 publication-title: Adv. Drug Delivery Rev. doi: 10.1016/j.addr.2017.04.010 – volume: 22 start-page: 6894 year: 2021 ident: D2FO02191A/cit37/1 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22136894 – volume: 13 start-page: 100 year: 2015 ident: D2FO02191A/cit14/1 publication-title: J. Transl. Med. doi: 10.1186/s12967-015-0465-5 – volume: 20 start-page: 582 year: 2012 ident: D2FO02191A/cit15/1 publication-title: J. Drug Targeting doi: 10.3109/1061186X.2012.697167 – volume: 35 start-page: 12 year: 2017 ident: D2FO02191A/cit3/1 publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2017.04.007 – volume: 7 start-page: 165 year: 2015 ident: D2FO02191A/cit11/1 publication-title: World J. Hepatol. doi: 10.4254/wjh.v7.i2.165 – volume: 19 start-page: 1423 year: 2013 ident: D2FO02191A/cit27/1 publication-title: Nat. Med. doi: 10.1038/nm.3394 – volume: 12 start-page: 231 year: 2011 ident: D2FO02191A/cit32/1 publication-title: Nat. Immunol. doi: 10.1038/ni.1990 – volume: 9 start-page: 506 year: 2021 ident: D2FO02191A/cit2/1 publication-title: Biomater. Sci. doi: 10.1039/D0BM01142H – volume: 23 start-page: 142 year: 2021 ident: D2FO02191A/cit35/1 publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-021-02512-z – volume: 191 start-page: 1056 year: 2018 ident: D2FO02191A/cit39/1 publication-title: Chemosphere doi: 10.1016/j.chemosphere.2017.08.070 – volume: 12 start-page: 660065 year: 2021 ident: D2FO02191A/cit19/1 publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.660065 – volume: 17 start-page: 674 year: 2018 ident: D2FO02191A/cit21/1 publication-title: Integr. Cancer Ther. doi: 10.1177/1534735418762537 – volume: 9 start-page: 46 year: 2019 ident: D2FO02191A/cit8/1 publication-title: Cells doi: 10.3390/cells9010046 – start-page: 187204 year: 2013 ident: D2FO02191A/cit10/1 publication-title: BioMed Res. Int. – volume: 103 start-page: 154228 year: 2022 ident: D2FO02191A/cit1/1 publication-title: Phytomedicine doi: 10.1016/j.phymed.2022.154228 – volume: 9 start-page: 619 year: 2013 ident: D2FO02191A/cit38/1 publication-title: Autophagy doi: 10.4161/auto.23546 – volume: 1835 start-page: 170 year: 2013 ident: D2FO02191A/cit4/1 publication-title: Biochim. Biophys. Acta – volume: 205 start-page: 192 year: 2019 ident: D2FO02191A/cit13/1 publication-title: Carbohydr. Polym. doi: 10.1016/j.carbpol.2018.10.028 – volume: 10 start-page: 1897295 year: 2021 ident: D2FO02191A/cit36/1 publication-title: OncoImmunology doi: 10.1080/2162402X.2021.1897295 – volume: 240 start-page: 527 year: 2016 ident: D2FO02191A/cit9/1 publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2016.07.018 – volume: 122 start-page: 787 year: 2012 ident: D2FO02191A/cit33/1 publication-title: J. Clin. Invest. doi: 10.1172/JCI59643 – volume: 22 start-page: 5196 year: 2021 ident: D2FO02191A/cit26/1 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22105196 – volume: 61 start-page: 335 year: 2011 ident: D2FO02191A/cit12/1 publication-title: Acta Pharm. doi: 10.2478/v10007-011-0030-6 – volume: 28 start-page: 200 year: 2014 ident: D2FO02191A/cit17/1 publication-title: Phytother. Res. doi: 10.1002/ptr.4980 – volume: 169 start-page: 2253 year: 2002 ident: D2FO02191A/cit31/1 publication-title: J. Immunol. doi: 10.4049/jimmunol.169.5.2253 |
SSID | ssj0000399898 |
Score | 2.467121 |
Snippet | The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 3155 |
SubjectTerms | Anticancer properties Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism CD86 antigen Cell activation Cytokines Cytokines - metabolism Ganoderma lucidum Hepatocellular carcinoma Heterogeneity Immunomodulation Inflammation Interleukin 10 Interleukin 27 Interleukin 6 Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Macrophages MAP kinase Mushrooms NF-kappa B - metabolism NF-κB protein Nitric-oxide synthase Phagocytes Phenotypes Phosphorylation Polarization Polysaccharides Polysaccharides - metabolism Polysaccharides - pharmacology Reishi - metabolism Saccharides Signal Transduction Signaling Tumor necrosis factor-α Tumors |
Title | The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36883482 https://www.proquest.com/docview/2793925699 https://www.proquest.com/docview/2784839598 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF6F9MIF8U9KQYugSKgyTby24z0mbdICacrBkXKzdte2aimxoyYGlZfhPbjwBjwTM_b6Jygg4OJE9mhjeb7s_PibGUJeBcy1mBn1jQhDFMtxIkOKLjdkZIeyq1zXzptVX0yd85n1fm7PW63vDdZStpFv1ZeddSX_o1U4B3rFKtl_0Gy1KJyA76BfOIKG4fjXOoYnExtXYFQ2KSbhc1apwgFBSboUTbrGKl3crIXCMqs4CNdFYcmZSHAYGkguMhUH2RLd0etiPj0mEZYCR3xdIbFnhUGwrto8-hSL3GW9GHz8APc_HRuHJ6PD4WB4hIQQUdS4g3P5WWy9Nh5jD2UEG5rTJgXgLEsNXagdV6SeWBhRWOxFntAWNn-JlGhZr4Z2lfj2RNrMZJgsJ8CwCntFvqQkq-ZkFD3yrt4TTawmciyuu2c3ztnd-dambjXA22_s0KxXtAXW1h7ndu20JF2GjVgDM0rBC-K9hr0sOQLTS388m0x8bzT3bpE9sw_OW5vsDUbeu0mV5oNlcEInjjgsb71sksv4cb38tlv0m1gn93m8u-SODlbooEDePdIKk_ukcwpPjr6muqPsgk7LgQ4PyFdAJN2BSFohkmpE0jSivyCSIiJphUiqEUnlDa0RSWtE0iYiKSCSAiIpIvIY8Pjj25BWWKQaiw_JbDzyTs4NPQLEUMzubQzGgtCMuCNkZCqn58IOYkmwFIGjpN0D2xhwCR6yI0AukBF8Ot1Q9RUEzYFSzGKPSDtJk_AJoU6IdG7mujK0LYlTHMBbVSbGB3DBijrkTakBX-n--DimZeHnPA3G_VNzfJlra9AhLyvZVdEVZqfUQalIX-8aa98Eg8ghzuC8Q15UlwHnqBGRhGmGMq4FgYvN3Q55XACg-hnmuC42pNr_8-JPye36L3ZA2pvrLHwG7vNGPtcQ_QlDlMxr |
linkProvider | Royal Society of Chemistry |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+anti-hepatocellular+carcinoma+effects+of+polysaccharides+from+Ganoderma+lucidum+by+regulating+macrophage+polarization+via+the+MAPK%2FNF-%CE%BAB+signaling+pathway&rft.jtitle=Food+%26+function&rft.au=Guo-li%2C+Li&rft.au=Jia-feng%2C+Tang&rft.au=Wen-li%2C+Tan&rft.au=Zhang%2C+Tao&rft.date=2023-04-03&rft.pub=Royal+Society+of+Chemistry&rft.issn=2042-6496&rft.eissn=2042-650X&rft.volume=14&rft.issue=7&rft.spage=3155&rft.epage=3168&rft_id=info:doi/10.1039%2Fd2fo02191a&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6496&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6496&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6496&client=summon |